Related Experiment Video
Updated: Jun 26, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Comparative docking studies of CYP1b1 and its PCG-associated mutant forms
Malkaram Sridhar Achary1, Hampapathalu Adimurthy Nagarajam
1Centre for DNA Fingerprinting and Diagnostics (CDFD),ECIL Road, Nacharam, Hyderabad 500 076, India.
Disease mutations in human CYP1B1 alter oestradiol binding. Molecular docking reveals altered interactions and geometry in mutants, impacting enzyme function and explaining disease mechanisms at a molecular level.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- The human CYP1B1 protein is crucial for enzyme catalysis.
- Mutations in CYP1B1 are associated with various diseases.
- Previous studies suggest mutations can destabilize functionally important protein regions.
Purpose of the Study:
- To investigate the binding modes of oestradiol with wild-type and mutant human CYP1B1.
- To understand how disease-associated mutations affect protein-ligand interactions and enzyme function.
Main Methods:
- Molecular docking simulations were performed.
- Receptor structures were derived from molecular dynamics simulations of homology models.
- Comparison of binding interactions between wild-type and mutant CYP1B1 proteins.
Main Results:
- Mutant CYP1B1 proteins exhibited altered protein-ligand interactions compared to the wild-type.
- Changes in substrate-binding region geometry and haem positioning were observed in mutants.
- A key difference was the loss or weakening of stacking interactions with phenyl residues in mutants.
Conclusions:
- Disease mutations in CYP1B1 significantly alter oestradiol binding interactions.
- These alterations in molecular function at the active site contribute to the deleterious nature of these mutations.
- The study provides molecular insights into the functional impact of CYP1B1 disease mutations.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
